About: Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 November 1984

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в листопаді 1984 (uk) article scientifique publié en 1984 (fr) im November 1984 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 01 November 1984 (en) artículu científicu espublizáu en payares de 1984 (ast)
publication date	wds:Q70389592-2BDAC8C9-B5E1-45FE-A2E5-3EBE1C809B17
publication date	1984-11-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q70389592-52007AB3-6F26-4D9C-8A26-736990BC668C
language of work or name	English
cites work	wds:Q70389592-079B62E6-5C6D-4C63-B61E-2006B0296C47 wds:Q70389592-0B9D2B72-E49A-47DC-9F0F-CEA838A09A5C wds:Q70389592-0D46E950-21B8-4B81-B505-165DD5F5EBBA wds:Q70389592-0EE495BC-D09D-4B32-9E87-C27442D61E5A wds:Q70389592-124FECFE-80FF-4619-8E25-EDD2ED8A5CEB wds:Q70389592-148FC1EF-7B54-4A7A-95E3-4E58A6777AD7 wds:Q70389592-1C7F9ACE-788F-4B0D-9F9D-10A74DAB763D wds:Q70389592-1C8EE9ED-0123-46DF-B7DE-2114429F4324 wds:Q70389592-270EA971-5E09-4AF9-BB3B-0F25AEB1BEEC wds:Q70389592-27C4F193-111D-4185-A64B-2161DA01C8D4 wds:Q70389592-2CD8442A-BFE8-4A17-8050-928E49E6A02B wds:Q70389592-2FF0972E-3D3A-4441-829B-F6E43CC5DC32 wds:Q70389592-31BA27B7-5571-426A-AD53-C3C169756656 wds:Q70389592-4230DD12-C33E-4730-9EE6-739883F9B8D7 wds:Q70389592-47F3D3BF-9DE0-4ECA-BEE3-C6C187437DEE wds:Q70389592-52F52BBC-F538-4374-9437-571C93480622 wds:Q70389592-546C817C-7888-4293-BAF7-CCF8C033E80B wds:Q70389592-5E4A28C6-9006-429F-B0F0-FC036F1742CB wds:Q70389592-6422A4A7-5058-4F9C-9997-E67F3B20EA72 wds:Q70389592-6883A3CF-97CF-445C-9E79-6EC6CE8A213A wds:Q70389592-749D355B-8744-445B-BEEA-CC47381612AB wds:Q70389592-80A6F258-F56B-4E21-8C06-DA2783641D66 wds:Q70389592-8343629C-489B-4073-A444-F7E768328C3E wds:Q70389592-84F2E71A-8DB7-48F5-BAF3-525D61ABF2BD wds:Q70389592-94A826C9-E389-4FEB-9C48-AE2082ACB9E7 wds:Q70389592-9A66F23A-71F6-459C-BB5C-006A91E7AB1B wds:Q70389592-A5661E20-052A-4F0B-8D74-A65BB19647EE wds:Q70389592-AC87C2E9-5419-448A-A708-4FAF74AA162D wds:Q70389592-B5E4C4A4-6EF6-4A81-9F27-34DBF01D3B80 wds:Q70389592-B682EE86-CBFB-4D74-AB5D-959E10018742 wds:Q70389592-B96807D0-50AE-4939-B58B-AB3A9AAC4462 wds:Q70389592-C03AB397-2697-401D-93BF-0574CF2E1A40 wds:Q70389592-CA37B2CA-1931-4305-9943-19B75CF755FD wds:Q70389592-D6077CFB-12DF-4EB6-A1CB-DFDBA0EAFB69 wds:Q70389592-DD6D6860-2605-4E6C-B14D-883D2BA7861E wds:Q70389592-DE939A85-6CB5-4DB7-98AE-1DACE392C1E9 wds:Q70389592-F12DEDC3-67D5-4884-A3BD-B7E4FE3C7184 wds:Q70389592-FE3287B1-AA61-4DC0-9D29-02627530302F wds:Q70389592-FF86FB1B-A633-41BC-8707-FE0F45E6DBC3
cites work	Treadmill exercise in assessment of the functional capacity of patients with cardiac disease The role of vasodilator therapy in heart failure Vasodilator therapy of cardiac failure: (first of two parts) Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo Echocardiographic determination of left ventricular stress-velocity relations Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm Vasodilator and inotropic therapy for severe chronic heart failure: Passion and skepticism Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure Cardiotonic activity of amrinone--Win 40680 [5-amino-3,4'-bipyridine-6(1H)-one] Amrinone: a new non-glycosidic, non-adrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in man Beneficial effects of amrinone-hydralazine combination on resting hemodynamics and exercise capacity in patients with severe congestive heart failure. Heart failure in outpatients: a randomized trial of digoxin versus placebo Hemodynamic assessment of amrinone. A new inotropic agent Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Assessment of vasodilator therapy in patients with severe congestive heart failure: Limitations of measurements of left ventricular ejection fraction and volumes Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure A Clinical Trial Design Avoiding Undue Placebo Treatment Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease Side effects of amrinone therapy Amrinone and exercise performance in patients with chronic heart failure Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients A new inotropic drug: its promise and a caution Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy Oral amrinone in refractory congestive heart failure Direct vasodilator and positive inotropic actions of amrinone Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease Relative sensitivity of echocardiography and systolic time intervals for assessing acute positive inotropic interventions in normal human subjects Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs Selection of vasodilator, inotropic or combined therapy for the management of heart failure. Acute substantial benefit of inotropic therapy with amrinone on exercise hemodynamics and metabolism in severe congestive heart failure Clinical assessment and follow-up of functional capacity in patients with chronic congestive cardiomyopathy Adverse effects of long-term amrinone administration in congestive heart failure New hope for the failing heart. The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure Cardiotonic agents in the management of chronic cardiac failure Effect of Amrinone, a cardiotonic drug, on hemodynamics and platelet function
author name string	wds:Q70389592-0A16B3B0-2E6C-4E52-9D65-695E07053412 wds:Q70389592-29072702-56AB-4106-8A6A-770D9B303431 wds:Q70389592-4BC1F32D-40F6-4376-92F2-1E10F04C4864 wds:Q70389592-E30815A5-B4C7-4801-95FB-0DBA9CBAF1AA wds:Q70389592-E35412EE-4F94-4140-93F7-E83F66F40AB0
author name string	R Shabetai J R Benotti C V Leier R DiBianco B D Silverman
rdfs:label	Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software